Skip to main content

Peer Review reports

From: Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial

Original Submission
7 May 2024 Submitted Original manuscript
3 Jan 2025 Reviewed Reviewer Report
23 Jan 2025 Reviewed Reviewer Report
4 Mar 2025 Author responded Author comments - Qingqing Cai
21 Mar 2025 Reviewed Reviewer Report
25 Mar 2025 Reviewed Reviewer Report
16 Apr 2025 Author responded Author comments - Qingqing Cai
Resubmission - Version 2
4 Mar 2025 Submitted Manuscript version 2
Publishing
25 Apr 2025 Editorially accepted
6 May 2025 Article published 10.1186/s12916-025-04103-0

You can find further information about peer review here.

Back to article page